IM Cannabis (IMCC) Registration Filing summary

Company overview and business model

• Operates as an international medical cannabis provider, focusing on Israel and Germany, leveraging a transnational ecosystem and data-driven approach for supply chain and patient insights.

• Shifted strategic focus to Germany after partial legalization in April 2024, aiming for significant growth in the expanding medical cannabis market.

• Maintains retail operations in Israel, including licensed pharmacies, online platforms, and home delivery, enhancing direct patient access and brand recognition.

• German operations are anchored by a logistics center and EU-GMP production facility, enabling import, repackaging, and third-party services.

Financial performance and metrics

• As of March 31, 2025: cash and cash equivalents were $1.389 million CAD; total debt was $9.711 million CAD; total equity stood at $5.234 million CAD; total capitalization was $15.035 million CAD.

• On June 26, 2025, the aggregate market value of common shares held by non-affiliates was approximately $15.89 million, with 4,044,812 shares outstanding.

Use of proceeds and capital allocation

• Net proceeds from the offering are intended for working capital and general corporate purposes, with management retaining broad discretion over allocation based on operational and market factors.